Catriona Yale - Dec 14, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Dec 14, 2023
Transactions value $
-$12,394
Form type
4
Date filed
12/18/2023, 08:49 PM
Previous filing
Dec 12, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$12.4K -597 -0.76% $20.76 77.9K Dec 14, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.